Poly Medicure Limited — Investor Meet, 14-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Poly Medicure reported Q2 consolidated revenue of Rs 444 Cr (+5.7% YoY) and PAT of Rs 92 Cr. H1 revenue reached Rs 847 Cr (+5.3% YoY) with PAT at Rs 185 Cr (+14.5% YoY), maintaining an operating EBITDA margin of 26.7%.

The company recently acquired Italy's Citieffe Group (ortho trauma) and Netherlands' PendraCare (cardiology), adding an estimated Rs 280 Cr in annual revenue. It expects FY26 revenue growth of 15-16%, with H2 revenue guided at Rs 1,080-1,090 Cr (+25% over H1), signaling a recovery. Domestic business remains strong, growing 17-18% YoY. While international markets show green shoots, Europe faces headwinds, and US expansion is affected by tariffs. Management is confident in the growth trajectory, driven by new product launches and capacity expansion.